Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Irinotecan Sucrosofate · MM-398, PEP-02

Small molecule · Inhibitor of Topoisomerase I (TOP1) · developed by AstraZeneca

Phase 2 Most advanced trial
AZN Developer
2 Registered trials

What is Irinotecan Sucrosofate?

Irinotecan sucrosofate is a liposomal formulation of the camptothecin analogue irinotecan. The active metabolite SN-38 inhibits topoisomerase I, stabilizing DNA-enzyme complexes and causing lethal double-strand breaks. It is studied in pancreatic, gastric, gastroesophageal junction, and biliary tract cancers.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
MM-398, PEP-02, Irinotecan liposome, Nanoliposomal Irinotecan
Drug type
Small molecule
Targets
Topoisomerase I (TOP1)
Mechanism
Inhibitor of Topoisomerase I (TOP1)
Pathways
DNA damage, apoptosis
Therapy area
Oncology
Developer
AstraZeneca (AZN)
Also in trials of
IBRX
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
OL741S3N8B

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06219941 Phase 2 Gastric Cancer Recruiting AZN
NCT04390399 Phase 2 Pancreatic Cancer Active not recruiting IBRX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Biliary Tract CancerGastric CancerGastroesophageal Junction CancerPancreatic CancerPancreatic Ductal Adenocarcinoma

Other drugs acting on TOP1

Irinotecan FDA approved Tenifatecan Phase 1

More from AstraZeneca

Acalabrutinib FDA approved Anifrolumab FDA approved Benralizumab FDA approved Camizestrant FDA approved Durvalumab FDA approved Olaparib FDA approved Tremelimumab FDA approved Actinium Ac 225 FPI-2068 Phase 1 Adavosertib Phase 2 AZD0240 Phase 1 AZD4144 Phase 1 AZD4916 Phase 1

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the AZN page.

Follow AZN, the company behind Irinotecan Sucrosofate

See AZN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AZN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.